The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine

Exclusion Criteria

• •Family history of seizure, epilepsy, brain or mental disease
• •Subject allergic to any component of the investigational vaccine, or a more severe allergic reaction and history of allergies in the past.
• •Woman who is pregnant, breast-feeding on day of enrollment, or become pregnant during the next 12 months
• •Any acute fever disease or infections.
• •History of SARS
• •Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease.
• •Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc.
• •Hereditary angioneurotic edema or acquired angioneurotic edema
• •Urticaria in last one year
• •No spleen or functional spleen.
• •Platelet disorder or other bleeding disorder may cause injection contraindication
• •Faint at the sight of needles.
• •Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months.
• •Prior administration of blood products in last 4 months
• •Prior administration of other research medicines in last 1 month
• •Prior administration of attenuated vaccine in last 1 month
• •Prior administration of inactivated vaccine in last 14 days
• •Current anti-tuberculosis prophylaxis or therapy
• •According to the judgement of investigator,various medical, psychological, social or other conditions, those could affect the subjects to sign informed consent.